For: | Ding N, Che L, Li XL, Liu Y, Jiang LJ, Fan B, Tao JY, Chen X, Ji JF. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. World J Gastroenterol 2016; 22(6): 2071-2080 [PMID: 26877611 DOI: 10.3748/wjg.v22.i6.2071] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v22/i6/2071.htm |
Number | Citing Articles |
1 |
Chiara Raggi, Maria Letizia Taddei, Colin Rae, Chiara Braconi, Fabio Marra. Metabolic reprogramming in cholangiocarcinoma. Journal of Hepatology 2022; 77(3): 849 doi: 10.1016/j.jhep.2022.04.038
|
2 |
Fabiana Crispo, Michele Pietrafesa, Valentina Condelli, Francesca Maddalena, Giuseppina Bruno, Annamaria Piscazzi, Alessandro Sgambato, Franca Esposito, Matteo Landriscina. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives. Molecules 2020; 25(16): 3754 doi: 10.3390/molecules25163754
|
3 |
Christopher J. Pirozzi, Hai Yan. The implications of IDH mutations for cancer development and therapy. Nature Reviews Clinical Oncology 2021; 18(10): 645 doi: 10.1038/s41571-021-00521-0
|
4 |
Mete Ucdal, Ayse Burus, Basak Celtikci. The effect of genetics and biochemistry on the pathogenesis of cholangiocarcinoma. International Journal of Hepatobiliary and Pancreatic Diseases 2024; 14(2): 1 doi: 10.5348/100104Z04MU2024RV
|
5 |
Takeshi Suda, Takeshi Yokoo, Tsutomu Kanefuji, Kenya Kamimura, Guisheng Zhang, Dexi Liu. Hydrodynamic Delivery: Characteristics, Applications, and Technological Advances. Pharmaceutics 2023; 15(4): 1111 doi: 10.3390/pharmaceutics15041111
|
6 |
Peeranate Vanaroj, Wanna Chaijaroenkul, Kesara Na‑Bangchang. Notch signaling in the pathogenesis, progression and identification of potential targets for cholangiocarcinoma (Review). Molecular and Clinical Oncology 2022; 16(3) doi: 10.3892/mco.2022.2499
|
7 |
Jian Wang, Zhan-guo Zhang, Ze-yang Ding, Wei Dong, Hui-fang Liang, Liang Chu, Bi-xiang Zhang, Xiao-ping Chen. IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC. Journal of Surgical Research 2018; 231: 116 doi: 10.1016/j.jss.2018.04.056
|
8 |
Yan Zhu, Lawrence N. Kwong. Insights Into the Origin of Intrahepatic Cholangiocarcinoma From Mouse Models. Hepatology 2020; 72(1): 305 doi: 10.1002/hep.31200
|
9 |
Colm J. O’Rourke, Matthias S. Matter, Chirag Nepal, Rui Caetano‐Oliveira, Phuongnga T. Ton, Valentina M. Factor, Jesper B. Andersen. Identification of a Pan‐Gamma‐Secretase Inhibitor Response Signature for Notch‐Driven Cholangiocarcinoma. Hepatology 2020; 71(1): 196 doi: 10.1002/hep.30816
|
10 |
Tony El Jabbour, Attila Molnar, Stephen M. Lagana. Challenges in Diagnosing and Reporting Cholangiocarcinoma. Surgical Pathology Clinics 2023; 16(3): 599 doi: 10.1016/j.path.2023.04.012
|